PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes

被引:8
|
作者
Wilczek, Michael P. [1 ]
Armstrong, Francesca J. [1 ]
Mayberry, Colleen L. [1 ]
King, Benjamin L. [1 ,2 ]
Maginnis, Melissa S. [1 ,2 ]
机构
[1] Univ Maine, Dept Mol & Biomed Sci, Orono, ME 04469 USA
[2] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME 04469 USA
基金
美国国家卫生研究院;
关键词
JC polyomavirus; PML; astrocytes; SVGA cells; primary cells; PI3K; AKT; mTOR; rapamycin; wortmannin; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; LARGE T-ANTIGEN; JC VIRUS-DNA; MATRIX-METALLOPROTEINASE EXPRESSION; MULTIPLE-SCLEROSIS; BK POLYOMAVIRUS; GENE-EXPRESSION; CELL BIOLOGY; GLIAL-CELLS; PROTEIN;
D O I
10.3390/cells10113218
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Astrocytes are a main target of JC polyomavirus (JCPyV) in the central nervous system (CNS), where the destruction of these cells, along with oligodendrocytes, leads to the fatal disease progressive multifocal leukoencephalopathy (PML). There is no cure currently available for PML, so it is essential to discover antivirals for this aggressive disease. Additionally, the lack of a tractable in vivo models for studying JCPyV infection makes primary cells an accurate alternative for elucidating mechanisms of viral infection in the CNS. This research to better understand the signaling pathways activated in response to JCPyV infection reveals and establishes the importance of the PI3K/AKT/mTOR signaling pathway in JCPyV infection in primary human astrocytes compared to transformed cell lines. Using RNA sequencing and chemical inhibitors to target PI3K, AKT, and mTOR, we have demonstrated the importance of this signaling pathway in JCPyV infection of primary astrocytes not observed in transformed cells. Collectively, these findings illuminate the potential for repurposing drugs that are involved with inhibition of the PI3K/AKT/mTOR signaling pathway and cancer treatment as potential therapeutics for PML, caused by this neuroinvasive virus.
引用
收藏
页数:25
相关论文
共 50 条
  • [1] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [2] The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
    Su, Hengchuan
    Gu, Yanyun
    Li, Fengying
    Wang, Qidi
    Huang, Baoxing
    Jin, Xiaolong
    Ning, Guang
    Sun, Fukang
    PLOS ONE, 2013, 8 (04):
  • [3] RAS Signaling in the PI3K/AKT/MTOR Pathway
    Nussinov, Ruth
    Zhang, Mingzhen
    Jang, Hyunbum
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
  • [4] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [5] Stability Analysis of the PI3K–Akt–mTOR Signaling Pathway
    Sapega T.S.
    Guria G.T.
    Biophysics, 2020, 65 (2) : 259 - 267
  • [6] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
    Bhatt, Aadra P.
    Damania, Blossom
    FRONTIERS IN IMMUNOLOGY, 2013, 3
  • [7] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [8] PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes
    Wu, Xiaofeng
    Kihara, Takeshi
    Akaike, Akinori
    Niidome, Tetsuhiro
    Sugimoto, Hachiro
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 393 (03) : 514 - 518
  • [9] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [10] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450